Lung Cancer Clinical Trial

Airway Epithelium Gene Expression: AEGIS IDE

Summary

The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured. The investigators hypothesize that certain genes are expressed differently in current and former smokers who have lung cancer, and this difference in gene expression may be a biomarker for lung cancer.

View Full Description

Full Description

Allegro Diagnostics is funding this multi-center study to validate and extend a new diagnostic tool measuring global gene expression in airway epithelial cells obtained at routine bronchoscopy in suspect lung cancer patients. The test, which is highly sensitive and specific for lung cancer, measures the levels of expression of genes in cells brushed from the large bronchi during diagnostic bronchoscopy. Similar brushings of epithelial cells from the nose will be analyzed to determine if gene expression in these cells can be used as a screening tool in subjects who may have now or be at risk for developing lung cancer in the future.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients being evaluated for the diagnosis of possible lung cancer or "rule out lung cancer" and undergoing clinically indicated bronchoscopy
All patients are required to be at least 21 years of age and be able to understand and sign the informed consent form
Patient must be a current or former cigarette smoker

Exclusion Criteria:

A pulmonary physician does not recommend that bronchoscopy be performed
Inability to understand the written consent form and comply with requirements of the study
History of prior primary lung cancer
Immediately prior to bronchoscopy, the patient has been on a mechanical ventilator for >24 consecutive hours.

Study is for people with:

Lung Cancer

Estimated Enrollment:

1331

Study ID:

NCT00746759

Recruitment Status:

Completed

Sponsor:

Allegro Diagnostics, Corp.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 18 Locations for this study

See Locations Near You

University of Alabama
Birmingham Alabama, 35294, United States
Pulmonary Associates of Arizona
Phoenix Arizona, 85006, United States
University of California- Davis
Sacramento California, , United States
National Jewish Health
Denver Colorado, 80206, United States
Yale Univeristy
New Haven Connecticut, , United States
North Florida/South Georgia VA
Gainesville Florida, 32608, United States
Indiana University
Indianapolis Indiana, 46202, United States
LSU
New Orleans Louisiana, 70112, United States
St. Elizabeth's Medical Center
Boston Massachusetts, 02135, United States
University of Missouri
Columbia Missouri, 65203, United States
Pulmonary and Allergy Associates of New Jersey
Summit New Jersey, 07901, United States
Jamaica Hospital Medical Center
Jamaica New York, 11418, United States
Columbia University
New York New York, 10032, United States
Cleveland Clinic
Cleveland Ohio, , United States
University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States
Temple University
Philadelphia Pennsylvania, 19140, United States
Medical University of South Carolina
Charleston South Carolina, 29425, United States
Dorn VA
Columbia South Carolina, 29209, United States
Virginia Commonwealth University
Richmond Virginia, 23298, United States
Overlake Hospital
Bellevue Washington, 98004, United States
University of Wisconsin
Madison Wisconsin, 53792, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

1331

Study ID:

NCT00746759

Recruitment Status:

Completed

Sponsor:


Allegro Diagnostics, Corp.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider